 OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to primary disease site lung vs others, concurrent chemotherapy yes vs no, evidence of metastases yes vs no, and degree of weight loss 2-5 vs 6-10. Patients are randomized to 1 of 2 treatment arms. 